# Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis

> **NCT00628290** · PHASE2 · COMPLETED · sponsor: **University of Cologne** · enrollment: 42 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Cannabidiol
- **DRUG:** Amisulpride

## Key facts

- **NCT ID:** NCT00628290
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2004-11
- **Final completion:** 2008-03
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2008-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628290, "Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00628290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*